About the Authors
- Daniel B Costa, Susan T Schumer, Mark S Huberman, Daniel G Tenen, Susumu Kobayashi
- Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America
- Balázs Halmos
- University Hospitals of Cleveland and Case Western Reserve University, Cleveland, Ohio, United States of America
- Amit Kumar, Titus J Boggon
- Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut, United States of America
The authors have declared that no competing interests exist.
DBC conducted the experiments and analyzed the clinical and experimental data. AK and TJB generated the structural model of EGFR with secondary mutations and edited the manuscript. STS and MSH contributed to the clinical care, sample collection, and data acquisition of the gefitinib-resistant patients. BH and DGT supervised all aspects of this study including study design, execution, and interpretation. SK designed and conducted the experiments and analyzed the clinical and experimental data. DBC, BH, DGT and SK wrote the final manuscript.